PT  - JOURNAL ARTICLE
AU  - Pietro, R. Di
AU  - Basile, M.
AU  - Antolini, L.
AU  - Alberti, S.
TI  - Genetic drift versus regional spreading dynamics of COVID-19
AID  - 10.1101/2020.05.08.20095448
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.08.20095448
4099  - http://medrxiv.org/content/early/2020/07/23/2020.05.08.20095448.short
4100  - http://medrxiv.org/content/early/2020/07/23/2020.05.08.20095448.full
AB  - Background Current propagation models of COVID-19 pandemic spreading appear poorly consistent with existing epidemiological data and with evidence that SARS-CoV-2 is rapidly mutating, for potential aggressive evolution of the disease.Methods We thus challenged environmental versus genetic evolution models of COVID-19 spreading, in the largest epidemiological analysis conducted as yet. This was performed over 168,089 laboratory-confirmed infection cases in Italy, Spain and Scandinavia. Landmark dates were set for each of the countries analyzed at peak diffusion rates this date, and the doubling time versus cumulative number of diagnoses was computed. Diffusion data in Germany, France and UK constituted the validation dataset of our model, over 210,239 additional cases. Mutations and mutation rates of SARS-CoV-2 versus COVID-19 spreading were analyzed at nextstrain.org/ncov/europe.Results The mean doubling time of COVID-19 was 6.63 days in northern Italy, 5.87 days in central areas, and 5.38 days in southern Italy, for shorter COVID-19 doubling time in warmer regions. Spain extended this trend, with a mean COVID-19 doubling time of 4.2 days. Slower diffusion across progressively colder regions was observed in Scandinavia, with 9.4 days COVID-19 doubling time in Sweden, 10.8 days in Finland and 12.95 days in Norway. Such diffusion model was supported by SARS-CoV-2 mutation strings upon sequential diffusion across the North/South gradient.Conclusions Our findings indicate COVID-19 association to a sharp North/South climate gradient, with faster spreading in southern regions. Thus, warmer climate conditions may not limit SARS-CoV-2 diffusion. Very cold regions may be better spared by recurrent courses of SARS-CoV-2 infection.Competing Interest StatementSaverio Alberti is founder and CEO of Oncoxx BiotechFunding Statementfunding was provided to this research by the university of Messina and Oncoxx BiotechAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical committee by the University of MessinaAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data referred to in the manuscript are available as needed